

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## **Elfabrio**

(pegunigalsidase alfa-iwxj)

PHYSICIAN INFORMATION			PATIENT INFORMATION					
* Physician Name:  Specialty: * DEA, NPI		PLor TIN:	*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this					
			form are completed.*					
Office Contact Person:			* Patient Name:		Т			
Office Phone:			* Cigna ID: * Dat		* Date of Bir	Date of Birth:		
Office Fax:			* Patient Street Address:					
Office Street Address:			City:	State:		:	Zip:	
City:	State:	Zip:	Patient Phone:					
<b>Urgency:</b> ☐ Standard			cking this box, I attest to the fact that applying the standard review time frame may jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested: ☐ Elfabrio 20 mg/10 mL (2 mg/mL) ☐ Other (please specify):								
ICD10:								
Directions for use:		Dose:	Quantity:	· •	Dı	uration of The	erapy:	
Is this a new start or continuation of therapy with the requested medication? If patient has been taking samples, please pick "new start."  New start  Continuation of therapy								
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?								
Where will this medication be obtained?  Accredo Specialty Pharmacy**  Hospital Outpatient Retail pharmacy Other (please specify):			☐ Home Health / Home Infusion vendor ☐ Physician's office stock (billing on a medical claim form)  **Cigna's nationally preferred specialty pharmacy					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557								
Facility and/or doctor of Facility Name: Address (City, State, Zip C		nd administering m State:		Tax ID#:				
Is the patient a candidate for home infusion?							☐ Yes ☐ No	
Does the physician have an in-office infusion site?							☐ Yes ☐ No	
Where will this drug be ☐ Patient's Home ☐ Physician's Office ☐ Hospital Outpatient Oth								
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.								
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? (provide medical necessity rationale):								

Is the patient a candidate for home infusion?	Yes No No
Does the physician have an in-office infusion site?	Yes No No
What is your patient's diagnosis?  ☐ Fabry disease ☐ Other (please specify):	
Clinical Information:	
***This drug requires supportive documentation (i.e. genetic testing, chart notes, lab/test results,	etc). ***
Has the patient had a laboratory test demonstrating deficient alpha-galactosidase A activity in leukocytes or fibroblas	sts? ☐ Yes ☐ No
(if no) Has the patient had a molecular genetic test demonstrating pathogenic mutations in the galactosidas	e alpha gene? ☐ Yes ☐ No
Is the requested medication being prescribed by (or in consultation with) a geneticist, endocrinologist, a metabolic disspecialist, or a physician who specializes in the treatment of lysosomal storage disorders?	sorder sub- ☐ Yes ☐ No
While receiving Elfabrio, will your patient also be treated with Galafold (migalastat oral capsules)?	☐ Yes ☐ No
(if yes) Please provide the rationale for concurrent use.	
While receiving Elfabrio, will your patient also be treated with Fabrazyme (agalsidase beta intravenous infusion)?	☐ Yes ☐ No
(if yes) Please provide the rationale for concurrent use.	
Supportive documentation for all answers must be attached with this request.	
Please Provide any Additional Pertinent Clinical Information: (including: if the patient is currently on the re(with dates of use) and how they have been receiving it (samples, out of pocket, etc.):	requested drug
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the insurer its designees may perform a routine audit and request the medical information necessary to verify the a	
information reported on this form.  Prescriber Signature: Date:	
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScr	ipts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, i you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cign	t is important that

V090124

<sup>&</sup>quot;Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005